No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HIMS240712P20500
- 0.15
- -0.63-80.77%
15min DelayClose Jul 11 16:00 ET
0.38High0.13Low
0.38Open0.78Pre Close282 Volume508 Open Interest20.50Strike Price6.00KTurnover104.88%IV3.33%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.2784Delta0.3384Gamma120.29Leverage Ratio-0.2291Theta-0.0001Rho-33.49Eff Leverage0.0032Vega
Intraday
- 5D
- Daily
News
Hims & Hers Health Is Maintained at Buy by TD Cowen
Hims & Hers Health Is Maintained at Buy by TD
Hims & Hers Health Price Target Raised to $25.00/Share From $15.00 by TD Cowen
Hims & Hers Health Price Target Raised to $25.00/Share From $15.00 by TD
Piper Sandler Adjusts Price Target on Hims & Hers Health to $18 From $16, Maintains Neutral Rating
Hims & Hers Health (HIMS) has an average outperform rating and price target range of $13 to $26, according to analysts polled by Capital IQ.Price: 21.01, Change: +0.80, Percent Change: +3.96
Hims & Hers Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -11.11% Piper Sandler $16 → $18 Maintains Neutral 06/27/2024 13.58% Jefferies $14 → $23
Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)
TD Cowen Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $25
TD Cowen analyst Jonna Kim maintains $Hims & Hers Health(HIMS.US)$ with a buy rating, and adjusts the target price from $15 to $25.According to TipRanks data, the analyst has a success rate of 53.3%
Comments
Jim Cramer shared his perspective on Hims & Hers Health, highlighting its recent performance and potential. He suggested that while buying after its pullback to $20 from recent highs around $25 might be justified, caution is advised. Cramer noted the company's strength in telehealth services, particularly in areas like sexual health and mental health, which have seen robust growth.
He emphasized that while Hims & Hers has benefited from offering compounded ...
He emphasized that while Hims & Hers has benefited from offering compounded ...
From YouTube
7
Today grabbing
$Dave Inc(DAVE.US$
PT $41+ SL $27
$Desktop Metal(DM.US$
LT PT: $17+
$Hims & Hers Health(HIMS.US$
LT PT: $39.27+
$Intel(INTC.US$
PT: $50 SL: $25
Medium duration, 14-30 days min.
$Dave Inc(DAVE.US$
PT $41+ SL $27
$Desktop Metal(DM.US$
LT PT: $17+
$Hims & Hers Health(HIMS.US$
LT PT: $39.27+
$Intel(INTC.US$
PT: $50 SL: $25
Medium duration, 14-30 days min.
3
1. $Tesla(TSLA.US$ -- Often assessed by traditional auto industry metrics, Tesla's Full Self-Driving technology is overlooked, which shifts the focus from selling cars to providing autonomous ride services.
2. $SoFi Technologies(SOFI.US$ -- Regarded as just another fintech company, SoFi distinguishes itself with a unified financial platform that spans loan refinancing, investment services, and per...
2. $SoFi Technologies(SOFI.US$ -- Regarded as just another fintech company, SoFi distinguishes itself with a unified financial platform that spans loan refinancing, investment services, and per...
11
3
1. $Palantir(PLTR.US$
It is referred as the “Messi of AI”.
This is well deserved as customers are flocking to its AIP.
It allows companies to integrate their data and create customized LLMs for their operations.
This translated to a 40% year-over-year increase in U.S. commercial sales to $150 million and 27% worldwide commercial sales growth to $299 million.
Annual revenue is set to grow at 30% CAGR in the next 5 years.
2. $NVIDIA(NVDA.US$
...
It is referred as the “Messi of AI”.
This is well deserved as customers are flocking to its AIP.
It allows companies to integrate their data and create customized LLMs for their operations.
This translated to a 40% year-over-year increase in U.S. commercial sales to $150 million and 27% worldwide commercial sales growth to $299 million.
Annual revenue is set to grow at 30% CAGR in the next 5 years.
2. $NVIDIA(NVDA.US$
...
+1
22
1
$Hims & Hers Health(HIMS.US$ Jesus we get it guys you sold some fake fat pills relax people want skinny every thing diet is bad for you 😂
Read more